All Stories

  1. A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis
  2. Enhancing Cognitive Functions and Neuronal Growth through NPY1R Agonist and Ketamine Co-Administration: Evidence for NPY1R-TrkB Heteroreceptor Complexes in Rats
  3. Long‐term enhancements in antidepressant efficacy and neurogenesis: Effects of intranasal co‐administration of neuropeptide Y 1 receptor (NPY1R) and galanin receptor 2 (GALR2) agonists in the ventral hippocampus
  4. Enhancement of neurogenesis and cognition through intranasal co-delivery of galanin receptor 2 (GALR2) and neuropeptide Y receptor 1 (NPY1R) agonists: a potential pharmacological strategy for cognitive dysfunctions
  5. Plasma Concentrations of High Mobility Group Box 1 Proteins and Soluble Receptors for Advanced Glycation End-Products Are Relevant Biomarkers of Cognitive Impairment in Alcohol Use Disorder: A Pilot Study
  6. Effect of Cenobamate on Cognition in Patients with Drug-Resistant Epilepsy with Focal Onset Seizures: An Exploratory Study
  7. Epileptic and neurodevelopmental encephalopathy associated to SYNGAP1 mutation: Description of a case and treatment response to cannabidiol
  8. Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy
  9. Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies
  10. Comparing RNA extraction methods to face the variations in RNA quality using two human biological matrices
  11. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  12. Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations
  13. Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis
  14. Real‐world safety and effectiveness of cenobamate in patients with focal onset seizures: Outcomes from an Expanded Access Program
  15. Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder
  16. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy
  17. Functional outcomes of patients with NORSE and FIRES treated with immunotherapy: A systematic review
  18. Longitudinal Study of Cognitive Functioning in Adults with Juvenile Idiopathic Arthritis
  19. Design and validation of a questionnaire for monitoring neurological dysphagia and respiratory deterioration in patients with amyotrophic lateral sclerosis (DEREDELA)
  20. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  21. Immune Mechanism of Epileptogenesis and Related Therapeutic Strategies
  22. The cognitive and psychiatric subacute impairment in severe Covid-19
  23. Fracaso de un anticuerpo monoclonal anti-CGRP en el tratamiento de la migraña. ¿Tiene sentido probar otro?
  24. Current Status of Biomarkers in Anti-N-Methyl-D-Aspartate Receptor Encephalitis
  25. Prevalence of Neural Autoantibodies in Paired Serum and Cerebrospinal Fluid in Adult Patients with Drug-Resistant Temporal Lobe Epilepsy of Unknown Etiology
  26. Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA)
  27. The Cognitive and Psychiatric Subacute Impairment in severe Covid-19.
  28. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer’s disease
  29. Sudden cessation of fluoxetine before alcohol drinking reinstatement alters microglial morphology and TLR4/inflammatory neuroadaptation in the rat brain
  30. Efectos de la pandemia por Covid-19 sobre la calidad de vida de los pacientes con Esclerosis Lateral Amiotrófica
  31. FLAIR-hyperintense lesions in anti-MOG-associated encephalitis with seizures (FLAMES) in a patient with Crohn's disease on anti-TNF treatment
  32. Chronic central modulation of LPA/LPA receptors-signaling pathway in the mouse brain regulates cognition, emotion, and hippocampal neurogenesis
  33. GABAergic deficits in absence of LPA1 receptor, associated anxiety-like and coping behaviors, and amelioration by interneuron precursor transplants into the dorsal hippocampus
  34. Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis
  35. Environmental exposure to pesticides and Amyotrophic Lateral Sclerosis in the South of Spain
  36. Emergency implementation of telemedicine for epilepsy in Spain: Results of a survey during SARS-CoV-2 pandemic
  37. Miller‐Fisher syndrome after SARS‐CoV‐2 infection
  38. The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases
  39. Reader response: Neurologic complications of coronavirus infections
  40. Ofatumumab versus Teriflunomide in Multiple Sclerosis
  41. Neuroplasticity and Epilepsy Surgery in Brain Eloquent Areas: Case Report
  42. Implantación emergente de un servicio de Teleneurología en la Unidad de Neuromuscular del Hospital Regional de Málaga durante la pandemia por SARS-CoV-2
  43. Análisis de letalidad por COVID-19 en pacientes con demencia neurodegenerativa
  44. Incidence and case fatality rate of COVID-19 in patients with active epilepsy
  45. Influencia de la infección SARS-CoV-2 sobre enfermedades neurodegenerativas y neuropsiquiátricas: ¿una pandemia demorada?
  46. ¿Va a cambiar la neurología tras la pandemia de COVID-19 en los próximos 5 años? Estudio de enfoque mediante informadores clave
  47. Response to immunotherapy in anti‐IgLON5 disease: A systematic review
  48. Evaluación prequirúrgica mediante resonancia magnética funcional en pacientes con tumores neuroepiteliales disembrioplásicos: una serie de casos
  49. Clinical outcomes of eslicarbazepine acetate monotherapy for focal‐onset seizures: A multicenter audit
  50. Epileptic encephalopathy with phenotype pseudo-Dravet and missense mutation in the GRIN2A gene
  51. Miastenia grave inducida por tratamiento con inhibidores del punto de control inmunológico: primer caso secundario a avelumab y revisión de casos previamente publicados
  52. Factores asociados al mal control de la anticoagulación con antivitamina K en pacientes con fibrilación auricular no valvular atendidos en consultas de Medicina Interna y Neurología. Estudio ALADIN
  53. Consenso Delphi EPICON: recomendaciones sobre el manejo adecuado del cambio a acetato de eslicarbazepina en epilepsia
  54. Efficacy of antiepileptic drugs in autoimmune epilepsy: A systematic review
  55. Retrospective study of perampanel efficacy and tolerability in myoclonic seizures
  56. Estudio observacional multicéntrico español sobre el empleo de fármacos antiepilépticos en consultas de neurología
  57. Epidemiología de la epilepsia en España y Latinoamérica
  58. Eslicarbazepine acetate and carotid intima-media thickness in epileptic patients
  59. Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
  60. Awagrafia
  61. Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment
  62. Recomendaciones para el abordaje multidisciplinar del complejo esclerosis tuberosa
  63. Cognitive Profile of Zonisamide and Valproic Acid in the Treatment of Idiopathic Generalized Epilepsy: A Comparative Observational Study
  64. Adhesión al tratamiento con levetiracetam: estudio observacional retrospectivo no intervencionista
  65. Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial
  66. Role of high-dose levetiracetam as add-on therapy for intractable epilepsy: case report and brief review of the literature
  67. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab
  68. Adult Prevalence of Epilepsy in Spain: EPIBERIA, a Population-Based Study
  69. Tratamiento combinado con fármacos antiepilépticos. Guía Andaluza de Epilepsia 2015
  70. Early Add-on Lacosamide in a Real-Life Setting: Results of the REALLY Study
  71. Analysis of Factors Influencing Telephone Call Response Rate in an Epidemiological Study
  72. Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide
  73. International collaboration to assess the risk of Guillain Barré Syndrome following Influenza A (H1N1) 2009 monovalent vaccines
  74. Characteristics of temporal lobe epilepsy with no ictal impairment of consciousness
  75. Spatial recognition memory in a virtual reality task is altered in refractory temporal lobe epilepsy
  76. The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES)
  77. Validación en castellano de un cuestionario breve útil para cribado epidemiológico de epilepsia en España: Cuestionario EPIBERIA
  78. Acetato de eslicarbazepina en la práctica clínica. Resultados de eficacia y seguridad
  79. Zonisamida en el tratamiento de la epilepsia: revisión de la bibliografía desde la terapia añadida a la monoterapia
  80. Consenso de las Recomendaciones de Actuación diagnóstica y Terapéutica sobre Epilepsia resistente a fármacos antiepilépticos en España (Consenso RATE-España)
  81. Predictive model for refractoriness in Temporal Lobe Epilepsy based on clinical and diagnostic test data
  82. Cajal’s first steps in scientific research
  83. Spatial navigation impairment in patients with refractory temporal lobe epilepsy: Evidence from a new virtual reality-based task
  84. Factores vinculados a la adhesión al tratamiento en pacientes con epilepsia refractaria y no refractaria
  85. Antiepileptic treatment in patients with epilepsy and other comorbidities
  86. Vohwinkel Syndrome secondary to missense mutation D66H in GJB2 gene (connexin 26) can include epileptic manifestations
  87. Amnesia topográfica transitoria: descripción de una serie de ocho casos
  88. Possible case of peripheral osmotic demyelination syndrome
  89. Driving cost factors in adult outpatients with refractory epilepsy: A daily clinical practice in clinics of neurology in Spain
  90. Guía de práctica clínica de la Sociedad Andaluza de Epilepsia sobre profilaxis y tratamiento de las crisis epilépticas sintomáticas agudas
  91. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia sobre prescripción de fármacos antiepilépticos genéricos
  92. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia: recomendaciones terapéuticas ante una crisis epiléptica y en el estado epiléptico
  93. Guía de práctica clínica de consenso de la Sociedad Andaluza de Epilepsia para el diagnóstico y tratamiento del paciente con una primera crisis epiléptica en situaciones de urgencia
  94. Health and non-health care resources use in the management of adult outpatients with drug-resistant epilepsy in Spain: A cost-of-illness study (LINCE study)
  95. Possible case of peripheral osmotic demyelination syndrome
  96. Incidencia de ictus en España. Bases metodológicas del estudio Iberictus
  97. Pseudomigraña con pleocitosis y la ‘invisibilidad’ de las descripciones originales en castellano
  98. Clinical Implications of Mechanisms of Resistance to Antiepileptic Drugs
  99. Stiff person syndrome (SPS), a basal ganglia disease? Striatal MRI lesions in a patient with SPS
  100. Bilateral Bell Palsy and Acute HIV Type 1 Infection: Report of 2 Cases and Review
  101. Menstrual Tension-Type Headache: Evidence for Its Existence.
  102. A transcranial doppler study in interictal migraine and tension-type headache
  103. International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  104. Encefalomielitis aguda diseminada por picadura de himenóptero
  105. Avances en el conocimiento de la etiología y la fisiopatología de las epilepsias reflejas
  106. Cirugía de la epilepsia del lóbulo temporal: ¿es suficiente eliminar las crisis?
  107. Trombólisis en el ictus: la accesibilidad sin garantía de seguridad es insostenible
  108. Regarding: 'Mosaicism and seizure onset in ring chromosome 20 syndrome'
  109. The Red Ear Syndrome: Five New Cases
  110. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: II. Terapéutica antiepiléptica crónica en el adulto y en el niño
  111. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: III. Tratamiento antiepiléptico en situaciones especiales
  112. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: I. Criterios de inicio y cese y bases farmacológicas del tratamiento antiepiléptico
  113. Guía terapéutica en epilepsia de la Sociedad Andaluza de Epilepsia 2005: IV. Principios generales de politerapia antiepiléptica y estrategias terapéuticas en epilepsia refractaria
  114. Doppler transcraneal en el diagnóstico de fístula arteriovenosa pulmonar
  115. Infarto maligno de la arteria cerebral media: ¿tratamiento médico o quirúrgico?
  116. Hemorragia cerebral múltiple y antiagregantes plaquetarios
  117. Ring chromosome 20 epilepsy syndrome in children: Electroclinical features
  118. Paciente de 45 años con epilepsia refractaria del lóbulo temporal desde la infancia
  119. Epilepsia refractaria del adulto
  120. Comment: Fluorouracil-Induced Aphasia: Neurotoxicity versus Cerebral Ischemia
  121. Comment: fluorouracil-induced aphasia: neurotoxicity versus cerebral ischemia
  122. Epilepsia parcial refractaria a tratamiento médico y lesión porencefálica occipital
  123. Controversias en torno a los nuevos fármacos antiepilépticos
  124. El diagnóstico de la enfermedad cervical espondilótica: una revisión basada en la evidencia
  125. Caracterización epidemiológica de la epilepsia del adulto subsidiaria de ingreso hospitalario
  126. Pseudotumor inflamatorio: diagnóstico diferencial de los tumores del IV ventrículo
  127. Cromosoma 20 en anillo: ¿Una canalopatía epiléptica?
  128. Ischemic Stroke following Cisplatin and 5-Fluorouracil Therapy: A Transcranial Doppler Study
  129. Descripción histórica de la asociación de macroorquídia, retraso mental y dismorfia craneal en varones (Síndrome del cromosoma X frágil) por A. B. Richerand
  130. Hemodinámica cerebral en el síndrome de pseudomigraña con pleocitosis de LCR: un estudio Doppler transcraneal
  131. El diagnóstico de la esclerosis temporal mesial mediante imagen de resonancia magnética
  132. Correlación genotipo-fenotipo en la distrofia miotónica y predicción de la gravedad clínica
  133. Hemiatrofia facial progresiva de Parry-Romberg: consideraciones patogénicas y evolutivas a propósito de un caso con seguimiento prolongado
  134. Esclerosis temporal mesial (II): manifestaciones clínicas y estudios complementarios
  135. Pseudomigraine with temporary neurological symptoms and lymphocytic pleocytosis. A report of 50 cases
  136. Mediterranean spotted fever with central and peripheral neurological complications